72
Participants
Start Date
July 5, 2024
Primary Completion Date
March 3, 2025
Study Completion Date
June 5, 2025
50mg FHND1002
Participants will receive a daily oral dose of FHND1002 granules (50 mg) ,administered in the morning after fasting for at least 10 hours. The dose will be taken with 240 mL of water.
100mg FHND1002
Participants will receive a daily oral dose of FHND1002 granules (100 mg) , administered in the morning after fasting for at least 10 hours. The dose will be taken with 240 mL of water.
150 mg FHND1002
Participants will receive a daily oral dose of FHND1002 granules (150 mg), administered in the morning after fasting for at least 10 hours. The dose will be taken with 240 mL of water.
200 mg FHND1002（fasting）
Participants will receive a daily oral dose of FHND1002 granules (200 mg), administered in the morning after fasting for at least 10 hours. The dose will be taken with 240 mL of water.
250mg FHND1002
Participants will receive a daily oral dose of FHND1002 granules (250 mg), administered in the morning after fasting for at least 10 hours. The dose will be taken with 240 mL of water.
200mg FHND1002(postprandial)
Participants will receive a one-time dose (200 mg) under postprandial conditions
The first hospital of Lanzhou University, Lanzhou
Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.
INDUSTRY